Cite
HARVARD Citation
Ardini, E. et al. (n.d.). NMS-P088, a CSF-1R, FLT3 and KIT inhibitor with outstanding activity on gatekeeper resistance mutations, high tolerability, and potential for combination therapies. European journal of cancer. pp. S127-S128. [Online].